Nelson Dusetti, Head of the Translational Research and Innovative Therapies Department at the Cancer Research Centre of Marseille (CRCM), shared a post on LinkedIn about a paper he co-authored published on UEG Journal.
“Toward Precision Chemotherapy for Pancreatic Cancer Guided by Transcriptomic Signatures, published today in UEG Journal, retraces the scientific journey of theranostic prediction in pancreatic ductal adenocarcinoma highlighting the contribution of our institutions, the CRCM – Centre de Recherche en Cancérologie de Marseille and the Institut Paoli-Calmettes (IPC), to this field.
This review summarizes the main advances in treatment personalization, from GemPred and GemCore to the AI-assisted Pancreas-View algorithm, and discusses the future of transcriptomic-guided chemotherapy addressing current clinical limitations and ongoing prospective trials such as PACSign01, GemSign01, and NeoPREDICT.
Title: Toward Precision Chemotherapy for Pancreatic Cancer Guided by Transcriptomic Signatures
Authors: Brice Chanez, Matthieu Delaye, Nicolas Fraunhoffer, Juan Iovanna, Cindy Neuzillet, Nelson Dusetti
Read the full article on UEG Journal.
More posts featuring Nelson Dusetti on OncoDaily.
